CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

EpiVax lanza modelos mejorados con IA para la predicción de la inmunogenicidad

ISPRI™Positive
AI Analysis

Summary

EpiVax announced AI-enhanced improvements to its ISPRI platform for assessing immunogenicity risk in biopharmaceuticals. The update represents a routine product enhancement for the company's proprietary in silico technology.

Importance:3/10
Sentiment:
0.50
AIplatformimmunogenicityin silicoproduct launch

Read the original article

Published by PR Newswire Pharma on September 3, 2026 2:06 PM

Read Original